Following three clinical trials, the FDA has approved a new preventive treatment for neonates, infants, and toddlers that prevents respiratory syncytial virus (RSV) in those age populations.
The FDA has approved a treatment option for adults with multidrug resistant HIV infection, marking a “new class of antiretroviral medications” for this patient population.
The US Food and Drug Administration approved a drug for the treatment of HIV-1 infection in conjunction with other antiretroviral therapies among children aged at least 4 weeks who weigh at least 3 kg. ...
After performance data showed 95% sensitivity and specificity, the FDA authorized the assay’s marketing in the United States for detection of HIV-1 drug-resistant mutations.
After performance data showed 95% sensitivity and specificity, the FDA authorized the assay’s marketing in the United States for detection of HIV-1 drug-resistant mutations.
After a clinical trial showed positive results in 89% of participants, a new drug regimen was approved by the FDA for highly drug-resistant forms of pulmonary tuberculosis.
